Business Description
NextCure Inc
NAICS : 325412
SIC : 2834
ISIN : US65343E1082
Description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.98 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -18.7 | |||||
| 3-Year EPS without NRI Growth Rate | -19.2 | |||||
| 3-Year FCF Growth Rate | -0.7 | |||||
| 3-Year Book Growth Rate | -27.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 34.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.54 | |||||
| 9-Day RSI | 35.99 | |||||
| 14-Day RSI | 35.57 | |||||
| 6-1 Month Momentum % | -25.49 | |||||
| 12-1 Month Momentum % | 15.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.07 | |||||
| Quick Ratio | 9.07 | |||||
| Cash Ratio | 8.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | 2.83 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -58.41 | |||||
| ROA % | -50.79 | |||||
| ROIC % | -434.11 | |||||
| ROC (Joel Greenblatt) % | -518.3 | |||||
| ROCE % | -56.73 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.31 | |||||
| Price-to-Tangible-Book | 0.31 | |||||
| EV-to-EBIT | 0.77 | |||||
| EV-to-EBITDA | 0.81 | |||||
| EV-to-FCF | 1.04 | |||||
| Price-to-Net-Current-Asset-Value | 0.36 | |||||
| Price-to-Net-Cash | 0.38 | |||||
| Earnings Yield (Greenblatt) % | 129.87 | |||||
| FCF Yield % | -194.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NextCure Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.918 | ||
| Beta | 0.06 | ||
| Volatility % | 71.91 | ||
| 14-Day RSI | 35.57 | ||
| 14-Day ATR (€) | 0.02785 | ||
| 20-Day SMA (€) | 0.9953 | ||
| 12-1 Month Momentum % | 15.2 | ||
| 52-Week Range (€) | 0.846 - 2.275 | ||
| Shares Outstanding (Mil) | 28.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NextCure Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NextCure Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NextCure Inc Frequently Asked Questions
What is NextCure Inc(FRA:2US)'s stock price today?
The current price of FRA:2US is €0.90. The 52 week high of FRA:2US is €2.28 and 52 week low is €0.85.
When is next earnings date of NextCure Inc(FRA:2US)?
The next earnings date of NextCure Inc(FRA:2US) is 2025-03-21 Est..
Does NextCure Inc(FRA:2US) pay dividends? If so, how much?
NextCure Inc(FRA:2US) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers